Physician profile
John Koomen
NPI 1952466989
$1,739.40
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2020: $353 · 2021: $477 · 2022: $486 · 2023: $46.33 · 2024: $44.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $90.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $90.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $274.45 | 2019-2024 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $270.33 | 2019-2022 | |
| Allergan, INC. | $226.41 | 2020 | |
| Janssen Pharmaceuticals, INC | $170.43 | 2019-2024 | Spravato |
| Sunovion Pharmaceuticals INC. | $150.73 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.61 | 2021-2023 | |
| Abbvie INC. | $112.77 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $112.77 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $89.12 | 2021-2022 | |
| Lundbeck LLC | $45.24 | 2019 | |
| Axsome Therapeutics, INC. | $32.09 | 2023 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $30.51 | 2021 | |
| Supernus Pharmaceuticals, INC. | $30.26 | 2021 | |
| Almatica Pharma LLC | $27.15 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $14.49 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $14.35 | 2019 | |
| Bausch Health US, LLC | $12.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Koomen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.